A multicenter, prospective, non-interventional cohort study to evaluate the safety and treatment pattern of sodium zirconium cyclosilicate for hyperkalaemia management in real world practice in China

Trial Identifier: D9483R00001
Sponsor: AstraZeneca
NCTID:: NCT05271266
Start Date: March 2022
Primary Completion Date: December 2023
Study Completion Date: December 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Anshan, China
China Benxi, China
China Changsha, China
China Changshu, China
China Chengdu, China
China Dalian, China
China Handan, China
China Hangzhou, China
China Hefei, China
China Huhehaote, China
China Jiaxing, China
China Kunshan, China
China Linfen, China
China Nanjing, China
China Nanyang, China
China Ningbo, China
China Qidong, China
China Shijiazhuang, China
China Shiyan, China
China Taian, China
China Taixing, China
China Tianjin, China
China Wenzhou, China
China Xian, China
China Xinghua, China